FIELD: biotechnology.
SUBSTANCE: invention relates to a dual targeting compound capable of acting on fibroblast activation protein (FAP) and integrin αvβ3. Also disclosed is a radionuclide-labelled dual-targeting compound based on a target compound, method for production thereof and use in diagnosis or treatment of diseases characterized by high expression of fibroblast activation protein (FAP) and/or integrin αvβ3.
EFFECT: compound of the present invention and its radionuclide marker can synergistically affect a FAP target and an integrin target αvβ3 in tumours.
10 cl, 60 dwg, 2 tbl, 138 ex
Title | Year | Author | Number |
---|---|---|---|
DUAL TARGETING COMPOUND, METHOD FOR ITS PREPARATION AND USE | 2022 |
|
RU2838179C2 |
FIBROBLAST ACTIVATION PROTEIN INHIBITOR, MODIFIED BY TRUNCATED BLUE EVANS, METHOD FOR PREPARATION AND USE THEREOF | 2021 |
|
RU2841304C2 |
FAP INHIBITOR | 2019 |
|
RU2797409C2 |
LYOPHILIZATE FOR PREPARING RADIOPHARMACEUTICAL AGENT | 2017 |
|
RU2702238C2 |
MODIFIED CYANINE DYES AND THEIR CONJUGATES | 2020 |
|
RU2833355C2 |
RGD-CONTAINING PEPTIDOMIMETICS AND THEIR APPLICATION | 2009 |
|
RU2519736C2 |
VISUALISATION AGENTS | 2004 |
|
RU2355702C2 |
RGD-(BACTERIO)CHLOROPHYLL CONJUGATES FOR PHOTODYNAMIC THERAPY AND NECROTIC TUMOUR IMAGING | 2009 |
|
RU2518296C2 |
PEPTIDE-BASED COMPOUNDS FOR DIRECTED TRANSPORT TO INTEGRIN RECEPTORS | 2002 |
|
RU2303042C2 |
COMPOUND FOR DIAGNOSING TUMOURS EXPRESSING PSMA AND COMPOSITION BASED THEREON | 2019 |
|
RU2730507C1 |
Authors
Dates
2025-04-16—Published
2023-09-26—Filed